Literature DB >> 16083721

Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome.

Bao Luo1, Liping Tang, Zhishan Wang, Junlan Zhang, Yiqun Ling, Wenguang Feng, Ju-Zhong Sun, Cecil R Stockard, Andra R Frost, Yiu-Fai Chen, William E Grizzle, Michael B Fallon.   

Abstract

BACKGROUND & AIMS: Hepatic production and release of endothelin 1 plays a central role in experimental hepatopulmonary syndrome after common bile duct ligation by stimulating pulmonary endothelial nitric oxide production. In thioacetamide-induced nonbiliary cirrhosis, hepatic endothelin 1 production and release do not occur, and hepatopulmonary syndrome does not develop. However, the source and regulation of hepatic endothelin 1 after common bile duct ligation are not fully characterized. We evaluated the sources of hepatic endothelin 1 production after common bile duct ligation in relation to thioacetamide cirrhosis and assessed whether transforming growth factor beta1 regulates endothelin 1 production.
METHODS: Hepatopulmonary syndrome and hepatic and plasma endothelin 1 levels were evaluated after common bile duct ligation or thioacetamide administration. Cellular sources of endothelin 1 were assessed by immunohistochemistry and laser capture microdissection of cholangiocytes. Transforming growth factor beta1 expression and signaling were assessed by using immunohistochemistry and Western blotting and by evaluating normal rat cholangiocytes.
RESULTS: Hepatic and plasma endothelin 1 levels increased and hepatopulmonary syndrome developed only after common bile duct ligation. Hepatic endothelin 1 and transforming growth factor beta1 levels increased over a similar time frame, and cholangiocytes were a major source of each peptide. Transforming growth factor beta1 signaling in cholangiocytes in vivo was evident by increased phosphorylation and nuclear localization of Smad2, and hepatic endothelin 1 levels correlated directly with liver transforming growth factor beta1 and phosphorylated Smad2 levels. Transforming growth factor beta1 also stimulated endothelin 1 promoter activity, expression, and production in normal rat cholangiocytes.
CONCLUSIONS: Cholangiocytes are a major source of hepatic endothelin 1 production during the development of hepatopulmonary syndrome after common bile duct ligation, but not in thioacetamide-induced cirrhosis. Transforming growth factor beta1 stimulates cholangiocyte endothelin 1 expression and production. Cholangiocyte-derived endothelin 1 may be an important endocrine mediator of experimental hepatopulmonary syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083721      PMCID: PMC2830806          DOI: 10.1016/j.gastro.2005.05.050

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  44 in total

1.  Appearance of denuded hepatic stellate cells and their subsequent myofibroblast-like transformation during the early stage of biliary fibrosis in the rat.

Authors:  L H Tao; H Enzan; Y Hayashi; E Miyazaki; T Saibara; M Hiroi; M Toi; N Kuroda; K Naruse; Y L Jin; L M Guo
Journal:  Med Electron Microsc       Date:  2000

2.  Transforming growth factor betas and their receptors in human liver cirrhosis.

Authors:  H U Baer; H Friess; M Abou-Shady; P Berberat; A Zimmermann; L I Gold; M Korc; M W Büchler
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-12       Impact factor: 2.566

3.  Biliary cyst fluid from common bile duct-ligated rats stimulates endothelial nitric oxide synthase in pulmonary artery endothelial cells: a potential role in hepatopulmonary syndrome.

Authors:  L Liu; M Zhang; B Luo; G A Abrams; M B Fallon
Journal:  Hepatology       Date:  2001-03       Impact factor: 17.425

Review 4.  The hepatopulmonary syndrome.

Authors:  P A Lange; J K Stoller
Journal:  Ann Intern Med       Date:  1995-04-01       Impact factor: 25.391

5.  The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression.

Authors:  A Inoue; M Yanagisawa; Y Takuwa; Y Mitsui; M Kobayashi; T Masaki
Journal:  J Biol Chem       Date:  1989-09-05       Impact factor: 5.157

6.  Cyclic AMP regulates cytokine stimulation of endothelin-1 release in human vascular smooth muscle cells.

Authors:  M Woods; E G Wood; J A Mitchell; T D Warner
Journal:  J Cardiovasc Pharmacol       Date:  2000-11       Impact factor: 3.105

7.  Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Authors:  Peter Schenk; Maximilian Schöniger-Hekele; Valentin Fuhrmann; Christian Madl; Gerd Silberhumer; Christian Müller
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

8.  Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats.

Authors:  C Thirunavukkarasu; Y Yang; V M Subbotin; S A K Harvey; J Fung; C R Gandhi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

9.  Endothelin-1 is synthesized and inhibits cyclic adenosine monophosphate- dependent anion secretion by an autocrine/paracrine mechanism in gallbladder epithelial cells.

Authors:  L Fouassier; T Chinet; B Robert; A Carayon; P Balladur; M Mergey; A Paul; R Poupon; J Capeau; V Barbu; C Housset
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

10.  Regulation of endothelin-1 synthesis by endothelin-converting enzyme-1 during wound healing.

Authors:  R Shao; W Yan; D C Rockey
Journal:  J Biol Chem       Date:  1999-01-29       Impact factor: 5.157

View more
  31 in total

1.  Elevated levels of endothelin-1 in hepatic venous blood are associated with intrapulmonary vasodilatation in humans.

Authors:  David G Koch; Galina Bogatkevich; Venkat Ramshesh; John J Lemasters; Renan Uflacker; Adrian Reuben
Journal:  Dig Dis Sci       Date:  2011-10-01       Impact factor: 3.199

2.  The TGFβ1 Receptor Antagonist GW788388 Reduces JNK Activation and Protects Against Acetaminophen Hepatotoxicity in Mice.

Authors:  Matthew McMillin; Stephanie Grant; Gabriel Frampton; Anca D Petrescu; Elaina Williams; Brandi Jefferson; Sharon DeMorrow
Journal:  Toxicol Sci       Date:  2019-05-01       Impact factor: 4.849

Review 3.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

4.  The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.

Authors:  Wenli Yang; Junlan Zhang; Bingqian Hu; Wei Wu; Julie Venter; Gianfranco Alpini; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-11-07       Impact factor: 4.052

Review 5.  Regulation of biliary proliferation by neuroendocrine factors: implications for the pathogenesis of cholestatic liver diseases.

Authors:  Md Kamruzzaman Munshi; Sally Priester; Eugenio Gaudio; Fuquan Yang; Gianfranco Alpini; Romina Mancinelli; Candace Wise; Fanyn Meng; Antonio Franchitto; Paolo Onori; Shannon S Glaser
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 6.  Advances in cholangiocyte immunobiology.

Authors:  Gaurav Syal; Michel Fausther; Jonathan A Dranoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-06       Impact factor: 4.052

7.  The relationship between hepatopulmonary syndrome and altitude.

Authors:  Morgan A Valley; James F Trotter; Deborah Thomas; Adit A Ginde; Steven R Lownenstein; Benjamin Honigman
Journal:  Can J Gastroenterol Hepatol       Date:  2014-03

Review 8.  Cholangiocyte proliferation and liver fibrosis.

Authors:  Shannon S Glaser; Eugenio Gaudio; Tim Miller; Domenico Alvaro; Gianfranco Alpini
Journal:  Expert Rev Mol Med       Date:  2009-02-25       Impact factor: 5.600

Review 9.  Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models.

Authors:  Sarah Raevens; Michael B Fallon
Journal:  Hepatology       Date:  2018-11       Impact factor: 17.425

10.  Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression.

Authors:  Giammarco Fava; Sharon Demorrow; Eugenio Gaudio; Antonio Franchitto; Paolo Onori; Guido Carpino; Shannon Glaser; Heather Francis; Monique Coufal; Luca Marucci; Domenico Alvaro; Marco Marzioni; Trenton Horst; Romina Mancinelli; Antonio Benedetti; Gianfranco Alpini
Journal:  Liver Int       Date:  2009-03-09       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.